What is your approach to treatment in hormone receptor positive, HER2 negative (0 IHC) metastatic breast cancer with ERBB2 gene amplification after progression on AI and fulvestrant CDK4/6i with visceral crisis?
Answer from: Medical Oncologist at Community Practice
More information will be helpful in approaching this case.
Was this a de novo presentation or a recurrence case?
Was the ERBB2 IHC done on the primary tumor or a metastatic lesion?
Was the ERBB2 amplification detected in tissue (primary or metastatic)? At what point in time was this...
Comments
Medical Oncologist at Rocky Mountain Cancer Centers-Boulder
Recurrence in AI
Hepatic metastasis
Meta...
Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center Thank you @Austin for providing more informat...
Medical Oncologist at Rocky Mountain Cancer Centers-Boulder Thank you!
Medical Oncologist at Rocky Mountain Cancer Centers-Boulder Sorry to bother you again. Would you favor a TKI o...
Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center Not necessarily. I would consider Trastuzumab/Pert...
Medical Oncologist at NYU Winthrop Hospital T-DXd is approved in 2nd line therapy: DESTINY-Bre...
Recurrence in AI Hepatic metastasis Meta...
Thank you @Austin for providing more informat...
Thank you!
Sorry to bother you again. Would you favor a TKI o...
Not necessarily. I would consider Trastuzumab/Pert...
T-DXd is approved in 2nd line therapy: DESTINY-Bre...